anastrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   123 Trials   123 Trials   2738 News 


«12345678910111213...4142»
  • ||||||||||  anastrozole / Generic mfg.
    New P2 trial:  Study of 18F-FFNP Breast PET/MRI (clinicaltrials.gov) -  Oct 16, 2023   
    P2,  N=53, Not yet recruiting, 
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date:  A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) -  Oct 12, 2023   
    P1b,  N=198, Active, not recruiting, 
    An awareness of current drugs offered by MCCPDC and particularly those with a highly favorable price point may allow healthcare professionals to more effectively navigate the socioeconomic barriers to care often faced by patients. Trial completion date: Sep 2023 --> Dec 2024
  • ||||||||||  anastrozole / Generic mfg., tamoxifen / Generic mfg.
    Retrospective data, Journal:  Prophylaxis for Treatment-Induced Gynecomastia in Prostate Cancer Patients: A Network Meta-Analysis. (Pubmed Central) -  Oct 3, 2023   
    Daily Tamoxifen was the best prophylactic treatment choice, significantly better than RT, weekly Tamoxifen and Anastrozole. RT, weekly Tamoxifen and Anastrozole were significantly better than No Treatment/Placebo, but not daily Tamoxifen, in terms of prevention of treatment-induced gynecomastia in patients with prostate cancer.
  • ||||||||||  anastrozole / Generic mfg., tamoxifen / Generic mfg.
    Prophylaxis for Treatment-Induced Gynecomastia in Prostate Cancer Patients: A Network Meta-Analysis (Hall B2; In Person Only; Screen: 27) -  Oct 2, 2023 - Abstract #ASTRO2023ASTRO_2567;    
    RT, weekly Tamoxifen and Anastrozole were significantly better than No Treatment/Placebo, but not daily Tamoxifen, in terms of prevention of treatment-induced gynecomastia in patients with prostate cancer. Odd Ratio (OR, 95% CI) Anastrozole ANZ No Treatment NoTx Radiotherapy RT Tamoxifen Daily TMDQ Tamoxifen Weekly TMDW ANZ 1 0.27 [0.08, 0.97] 1.52 [0.36, 6.43] 7.21 [2.25,23.06] 1.15 [0.14, 9.54] NoTx 3.65 [1.03,12.93] 1 5.56 [2.58,11.95] 26.30 [10.42,66.40] 4.21 [0.57, 30.86] RT 0.66 [0.16,2.77] 0.18 [0.08,0.39] 1 4.73 [1.53, 14.61] 0.76 [0.09, 6.14] TMQD 0.14 [0.04,0.44] 0.04 [0.02,0.10] 0.21 [0.07,0.65] 1 0.16 [0.03, 0.93] TMQW 0.87 [0.10, 7.17] 0.24 [0.03, 1.74] 1.32 [0.16, 10.70] 6.25 [1.07, 36.43] 1
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Metastases:  KEYNOTE 287: A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer (clinicaltrials.gov) -  Oct 1, 2023   
    P1b,  N=100, Active, not recruiting, 
    Odd Ratio (OR, 95% CI) Anastrozole ANZ No Treatment NoTx Radiotherapy RT Tamoxifen Daily TMDQ Tamoxifen Weekly TMDW ANZ 1 0.27 [0.08, 0.97] 1.52 [0.36, 6.43] 7.21 [2.25,23.06] 1.15 [0.14, 9.54] NoTx 3.65 [1.03,12.93] 1 5.56 [2.58,11.95] 26.30 [10.42,66.40] 4.21 [0.57, 30.86] RT 0.66 [0.16,2.77] 0.18 [0.08,0.39] 1 4.73 [1.53, 14.61] 0.76 [0.09, 6.14] TMQD 0.14 [0.04,0.44] 0.04 [0.02,0.10] 0.21 [0.07,0.65] 1 0.16 [0.03, 0.93] TMQW 0.87 [0.10, 7.17] 0.24 [0.03, 1.74] 1.32 [0.16, 10.70] 6.25 [1.07, 36.43] 1 Trial completion date: Sep 2023 --> Dec 2024
  • ||||||||||  anastrozole / Generic mfg., tamoxifen / Generic mfg.
    P3 data, Journal, Patient reported outcomes:  Dynamic Risk Prediction of Treatment Discontinuation Using Patient-Reported Outcomes Data in the Phase III NSABP B-35 Trial. (Pubmed Central) -  Sep 27, 2023   
    As for tamoxifen-treated patients, predictive factors included baseline BMI, and time-dependent covariates: cognitive problems, feelings of happiness, calmness, weight problems, and pain (Brier score 0.032, AUC 0.78, 95%CI 0.65-0.91). A real-time calculator based on these models was developed in Shiny to create a web-based application with a future goal to aid healthcare professionals in decision-making.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (clinicaltrials.gov) -  Sep 22, 2023   
    P2,  N=116, Active, not recruiting, 
    Thus, the TRPV4 channels act as sensors of extracellular and intracellular changes, making them potential therapeutic targets for alleviating pain related to aromatase inhibitors use, such as anastrozole. Recruiting --> Active, not recruiting | N=194 --> 116 | Trial primary completion date: Dec 2022 --> Dec 2024
  • ||||||||||  Verzenio (abemaciclib) / Eli Lilly
    Trial completion date, Metastases:  MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) -  Sep 21, 2023   
    P3,  N=463, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=194 --> 116 | Trial primary completion date: Dec 2022 --> Dec 2024 Trial completion date: Sep 2023 --> Dec 2024
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) -  Sep 15, 2023   
    P2,  N=161, Completed, 
    Trial completion date: Sep 2023 --> Dec 2024 Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2022 | Trial primary completion date: Jan 2024 --> Dec 2022
  • ||||||||||  anastrozole / Generic mfg.
    Journal:  Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer. (Pubmed Central) -  Sep 7, 2023   
    Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Dec 2022 | Trial primary completion date: Jan 2024 --> Dec 2022 BQ overexpression reverses the effect of anastrozole in ER+ve breast cancer in an AR-dependent manner, whilst co-treatment with the AR antagonist bicalutamide recovered its therapeutic effect both in vitro and in vivo.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    Trial completion date, Trial primary completion date:  Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (clinicaltrials.gov) -  Sep 6, 2023   
    P1/2,  N=44, Active, not recruiting, 
    Results justify further investigation in ongoing trials. Trial completion date: Jul 2023 --> Dec 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
  • ||||||||||  camizestrant (AZD9833) / AstraZeneca
    Trial completion date, Trial primary completion date:  SERENA-1: Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (clinicaltrials.gov) -  Aug 28, 2023   
    P1,  N=403, Recruiting, 
    Trial completion date: Oct 2023 --> Jan 2028 | Trial primary completion date: Oct 2023 --> Jan 2025 Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: May 2024 --> Aug 2024
  • ||||||||||  Review, Journal, BRCA Biomarker:  Chemoprevention and Lifestyle Modifications for Risk Reduction in Sporadic and Hereditary Breast Cancer. (Pubmed Central) -  Aug 26, 2023   
    Lifestyle modifications can reduce breast cancer incidence, and the recommendations for BRCA 1 or BRCA 2 P/LP germline variant carriers are comparable to the general population. This review summarizes the most recent evidence regarding the efficacy of chemoprevention and lifestyle interventions in women with sporadic and hereditary breast cancer.
  • ||||||||||  anastrozole / Generic mfg., fulvestrant / Generic mfg.
    Journal:  Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226. (Pubmed Central) -  Aug 24, 2023   
    In an exploratory analysis, participants with low CYP2C9 activity had lower anastrozole concentrations and higher fulvestrant concentrations than participants with high CYP2C9 activity. Inherited genetic variation in CYP3A4 and CYP2C9 may affect concentrations of endocrine therapy and may be useful to personalize dosing and improve treatment outcomes.
  • ||||||||||  Phase classification, Enrollment change:  SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) -  Aug 8, 2023   
    P1,  N=25, Not yet recruiting, 
    Trial completion date: Aug 2023 --> Dec 2023 Phase classification: P2 --> P1 | N=131 --> 25
  • ||||||||||  anastrozole / Generic mfg.
    A Case of Gastric Metastasis Presenting as Dysphagia and Odynophagia (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_3245;    
    Case Description/ A 56-year-old female with significant past medical history of acid reflux requiring multiple esophagogastroduodenoscopies (EGD) with esophageal dilations, left invasive lobular breast carcinoma treated with chemotherapy along with bilateral mastectomy and chemoradiation fifteen years ago presented to an outpatient oncology clinic for worsening backpain in 2020 after being in complete remission with ten years of Anastrozole therapy...Our case reiterates the importance of considering gastric metastasis as a potential differential in patients with a history of breast carcinoma, regardless of onset of the cancer, who present with upper gastrointestinal symptoms. Figure: Figure 1: Gastric metastatic lesion secondary to breast carcinoma in the fundus of stomach (yellow arrow).
  • ||||||||||  War and the fragility of anticancer drug supply networks in Ukraine () -  Jul 27, 2023 - Abstract #ESMO2023ESMO_3203;    
    10 (32%) were limited per 9-12: ibrutinib, mercaptopurine, eltrombopag, erythropoietin, thrombopoietin, ruxolitinib, venetoclax, brentuximab, gemtuzumab, obinutuzumab...Conclusions Shortages of essential anticancer drugs are a continued challenge in Ukraine during the war. Results are limited by small sample size and limited sampling from regions affected by active hostilities.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Invasive disease (Bilbao Auditorium - NCC) -  Jul 27, 2023 - Abstract #ESMO2023ESMO_1283;    
    P3
    EBC. Table: LBA23 Tx, n 3-y iDFS rate, % HR (95% CI) Menopausal status Premenopausal women & men Postmenopausal women RIB + NSAI, 1126 NSAI alone, 1132 RIB + NSAI, 1423 NSAI alone, 1420 91 89 90 86 0.72 (0.53-0.98) 0.78 (0.61-1.00) Anatomical stage II III RIB + NSAI, 1011 NSAI alone, 1034 RIB + NSAI, 1528 NSAI alone, 1512 94 91 87 84 0.76 (0.53-1.10) 0.74 (0.59-0.93) Nodal status N0 N1-N3 RIB + NSAI, 285 NSAI alone, 328 RIB + NSAI, 2261 NSAI alone, 2219 94 89 90 87 0.63 (0.34-1.17) 0.77 (0.63-0.94) Age 20% RIB + NSAI, 1199 NSAI alone, 1236 RIB + NSAI, 920 NSAI alone, 938 92 90 89 84 0.80 (0.59-1.08) 0.75 (0.56-1.00)
  • ||||||||||  anastrozole / Generic mfg., fulvestrant / Generic mfg.
    Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-na (Bilbao Auditorium - NCC) -  Jul 27, 2023 - Abstract #ESMO2023ESMO_796;    
    P3
    Table: LBA23 Tx, n 3-y iDFS rate, % HR (95% CI) Menopausal status Premenopausal women & men Postmenopausal women RIB + NSAI, 1126 NSAI alone, 1132 RIB + NSAI, 1423 NSAI alone, 1420 91 89 90 86 0.72 (0.53-0.98) 0.78 (0.61-1.00) Anatomical stage II III RIB + NSAI, 1011 NSAI alone, 1034 RIB + NSAI, 1528 NSAI alone, 1512 94 91 87 84 0.76 (0.53-1.10) 0.74 (0.59-0.93) Nodal status N0 N1-N3 RIB + NSAI, 285 NSAI alone, 328 RIB + NSAI, 2261 NSAI alone, 2219 94 89 90 87 0.63 (0.34-1.17) 0.77 (0.63-0.94) Age 20% RIB + NSAI, 1199 NSAI alone, 1236 RIB + NSAI, 920 NSAI alone, 938 92 90 89 84 0.80 (0.59-1.08) 0.75 (0.56-1.00) Conclusions At the final analysis of FALCON, no significant difference in OS was seen between fulvestrant and anastrozole in ET-na
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Metastases:  POLLY: ER Reactivation Therapy for Breast Cancer (clinicaltrials.gov) -  Jul 20, 2023   
    P2,  N=19, Active, not recruiting, 
    Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Jun 2023 Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: May 2023 --> Oct 2023
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Preclinical, Journal:  In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment. (Pubmed Central) -  Jul 18, 2023   
    Trial completion date: Sep 2023 --> Apr 2024 | Trial primary completion date: May 2023 --> Oct 2023 This is the first in vitro study that highlights the potential benefit of G as an adjuvant therapy with Exe, emphasizing, however, that soy derivatives widely used in the diet or applied as auxiliary medicines may increase the risk of adverse interactions with nonsteroidal AIs used in therapy.